Cardiac Resynchronization Therapy With or Without Defibrillation: A Long-Standing Debate.

Area of Science:

• Cardiology
• Biomedical Engineering

Background:

• Cardiac resynchronization therapy (CRT) benefits patients with severe left ventricular dysfunction and conduction disturbances.
• CRT is delivered via pacemaker (CRT-P) or defibrillator (CRT-D) systems.
• CRT-D offers arrhythmic death prevention, but benefits may vary by heart failure etiology.

Purpose of the Study:

• To evaluate the comparative advantages and disadvantages of CRT-P versus CRT-D devices.
• To discuss patient-tailoring device selection when defibrillator indications are absent.
• To identify factors influencing the choice between CRT-P and CRT-D.

Main Methods:

• Review of existing literature on CRT device efficacy and cost-effectiveness.
• Analysis of factors influencing device selection, including patient characteristics and device complications.
• Consideration of decision-making tools like the Goldenberg score.

Main Results:

• CRT-Ds have higher hardware complexity, risk of malfunction, and shorter battery life.
• CRT-Ps may be more cost-effective for nonischemic cardiomyopathy without prior arrhythmias.
• Patient-tailored selection is crucial, considering age, comorbidities, and arrhythmia risk.

Conclusions:

• The optimal choice between CRT-P and CRT-D requires careful patient assessment.
• Factors like comorbidities, infection risk, and cost-effectiveness influence device selection.
• Further randomized trials are needed to compare CRT-P and CRT-D efficacy and safety.